Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease

Protalix BioTherapeutics Inc PLX and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have announced final results from the BRIGHT Phase 3 trial of pegunigalsidase alfa (PRX‑102) for Fabry disease. 

  • The results indicate that treatment with 2 mg/kg of PRX-102 administered by intravenous (IV) infusion every four weeks was well tolerated.
  • Fabry disease, assessed by estimated glomerular filtration rate (eGFR) slope and plasma lyso-Gb3 concentration was stable.
  • PRX-102 is a plant cell-expressed recombinant, PEGylated, cross-linked α‑galactosidase‑A product candidate. 
  • Overall, 33 of 182 total treatment-emergent adverse events (TEAEs) reported in nine (30.0%) patients were considered treatment-related; all were mild or moderate in severity, and the majority were resolved at the end of the study. 
  • Additional long-term data is being collected as part of an extension study.
  • Recently, Protalix submitted a European marketing application for pegunigalsidase alfa for Fabry disease.
  • Price Action: PLX shares are up 15.4% at $1.07 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!